Alembic Pharma (Oral Solids ==> Injectables, Onco, Derma, Opthalmic)

Q2Fy21 Financial Highlights

  • Sales up 17% YoY
  • Net Profit up 35% YoY

International Business

  • 6 ANDA approvals received during the quarter; 131 Cumulative ANDA approvals.
  • 7 ANDA filings during the quarter; Cumulative ANDA filings at 198

API Business

  • 2 DMF were filed in the quarter

Source: https://www.bseindia.com/xml-data/corpfiling/AttachLive/730360f2-d967-4d14-ade4-d076112d9db3.pdf

28 Likes